Completed PHASE1 INTERVENTIONAL 1-arm NCT00387205

Study To Assess Long Term Safety Of Pazopanib

An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients

Sponsor: Novartis Pharmaceuticals

Interventions Pazopanib

Updated 12 times since 2017 Last updated: Mar 4, 2019 Started: Jun 20, 2006 Primary completion: Feb 13, 2013 Completion: Mar 8, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Carcinoma, Renal Cell, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 12 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 7 earlier versions

Mar 2019 — Apr 2019 [monthly]

Completed PHASE1
Nov 2018 — Mar 2019 [monthly]

Completed PHASE1
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2017 — May 2018 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Buffalo, United States , Cleveland, United States , Detroit, United States , Duarte, United States , Durham, United States , Greenville, United States , Houston, United States , Indianapolis, United States , Lebanon, United States and 9 more locations